ONCY bispecific in development (pelareorep x CD3)May 2021 - Collaborative preclinical studies with LUMC is evaluating the combination of pelareorep-CD3-bispecific antibody combinations in breast and pancreatic tumor models.
Pelareorep's clinically demonstrated ability to recruit T cells to solid tumors provides a strong rationale for these studies, as CD3-bispecific antibodies are designed to facilitate cancer-killing by simultaneously engaging both T cells and tumor tissue.
Prior preclinical studies in breast and pancreatic cancer models also support this collaboration, as they have shown that the addition of pelareorep to CD3-bispecific antibody therapy results in cancer regression and prolonged survival.
https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-2021-first-quarter-development-highlights-and-financial-results-301286355.html
Roche's Lunsumio is the first CD20xCD3 bispecific antibody approved anywhere.
https://www.fiercepharma.com/pharma/roches-bispecific-blood-cancer-drug-lunsumio-treads-car-ts-turf-global-first-nod